These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 24029546

  • 1. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
    Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G, ALLEGRO Study Group.
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):851-8. PubMed ID: 24029546
    [Abstract] [Full Text] [Related]

  • 2. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, ALLEGRO Study Group.
    N Engl J Med; 2012 Mar 15; 366(11):1000-9. PubMed ID: 22417253
    [Abstract] [Full Text] [Related]

  • 3. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
    Mult Scler; 2022 Apr 15; 28(4):608-619. PubMed ID: 34378456
    [Abstract] [Full Text] [Related]

  • 4. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
    Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, BRAVO Study Group.
    J Neurol; 2014 Apr 15; 261(4):773-83. PubMed ID: 24535134
    [Abstract] [Full Text] [Related]

  • 5. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5062 Study Group.
    Lancet; 2008 Jun 21; 371(9630):2085-92. PubMed ID: 18572078
    [Abstract] [Full Text] [Related]

  • 6. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L, FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.
    Arch Neurol; 2012 Oct 21; 69(10):1259-69. PubMed ID: 22751847
    [Abstract] [Full Text] [Related]

  • 7. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.
    Traboulsee A, Dehmeshki J, Peters KR, Griffin CM, Brex PA, Silver N, Ciccarrelli O, Chard DT, Barker GJ, Thompson AJ, Miller DH.
    Mult Scler; 2003 Dec 21; 9(6):566-73. PubMed ID: 14664468
    [Abstract] [Full Text] [Related]

  • 8. Imaging axonal damage of normal-appearing white matter in multiple sclerosis.
    Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL.
    Brain; 1998 Jan 21; 121 ( Pt 1)():103-13. PubMed ID: 9549491
    [Abstract] [Full Text] [Related]

  • 9. The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography.
    Pardini M, Botzkowski D, Müller S, Vehoff J, Kuhle J, Ruberte E, Würfel J, Gass A, Valmaggia C, Tettenborn B, Putzki N, Yaldizli Ö.
    Eur J Neurol; 2016 Dec 21; 23(12):1769-1774. PubMed ID: 27591406
    [Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
    Giovannoni G, Knappertz V, Steinerman JR, Tansy AP, Li T, Krieger S, Uccelli A, Uitdehaag BMJ, Montalban X, Hartung HP, Pia Sormani M, Cree BAC, Lublin F, Barkhof F.
    Neurology; 2020 Aug 25; 95(8):e1027-e1040. PubMed ID: 32651286
    [Abstract] [Full Text] [Related]

  • 11. White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI.
    Mühlau M, Buck D, Förschler A, Boucard CC, Arsic M, Schmidt P, Gaser C, Berthele A, Hoshi M, Jochim A, Kronsbein H, Zimmer C, Hemmer B, Ilg R.
    Mult Scler; 2013 Oct 25; 19(11):1485-92. PubMed ID: 23462349
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R.
    J Neurol Neurosurg Psychiatry; 2008 Apr 25; 79(4):407-14. PubMed ID: 17550987
    [Abstract] [Full Text] [Related]

  • 14. The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI study.
    Ceccarelli A, Rocca MA, Pagani E, Ghezzi A, Capra R, Falini A, Scotti G, Comi G, Filippi M.
    Neuroimage; 2008 Feb 15; 39(4):1499-509. PubMed ID: 18155611
    [Abstract] [Full Text] [Related]

  • 15. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis.
    Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O.
    Neuroimage; 2004 Apr 15; 21(4):1825-9. PubMed ID: 15050603
    [Abstract] [Full Text] [Related]

  • 16. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
    Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V, Khan O.
    J Neurol; 2015 Mar 15; 262(3):648-53. PubMed ID: 25542295
    [Abstract] [Full Text] [Related]

  • 17. Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.
    Mesaros S, Rocca M, Sormani M, Valsasina P, Markowitz C, De Stefano N, Montalban X, Barkhof F, Ranjeva J, Sailer M, Kappos L, Comi G, Filippi M.
    Mult Scler; 2010 Mar 15; 16(3):325-31. PubMed ID: 20086023
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.